Ingrid Yao Mattisson et al, ACS Omega, 2023
Summary
Although much progress has been made over the last decades, there is still a significant clinical need for novel therapies to manage cancer. Typical problems are that solid tumors are frequently inaccessible, aggressive, and metastatic. To contribute to solving some of these issues, we have developed a novel radioisotope-labeled 27 nm nanoparticle, 177Lu-SN201, to selectively target solid tumors via the enhanced permeability and retention effect, allowing irradiation intratumorally. We show that 177Lu-SN201 has robust stealth properties in vitro and anti-tumor efficacy in mouse mammary gland and colon carcinoma models. The possible clinical application is also addressed with single photon emission computed tomography imaging, which confirms uptake in the tumor, with an average activity of 19.4% injected dose per gram (ID/g). The properties of 177Lu-SN201 make it a promising new agent for radionuclide therapy with the potential to target several solid tumor types.
Results from nanoScan® SPECT/CT
Mice treated with 177Lu-SN201 showed a reduced tumor growth rate without signs of radiotoxicity. The best-fit values of tumor doubling time were 11 days for the 177Lu-SN201-treated and 6 days for the vehicle-treated group (p < 0.05) (Figure 5A).
Figure 5. Anti-tumor efficacy and SPECT/CT imaging of 177Lu-SN201. (A) Mean body weight ± SD and (B) relative tumor volume in MC38 tumor-bearing mice after treatment with 4 MBq/mouse (n = 18) 177Lu-SN201 vs vehicle (n = 10). (C) Representative SPECT/CT images of maximum intensity projection and tumor region of interest (ROI) definitions in the coronal, sagittal, and transverse view, 72 h post-treatment with 4 MBq 177Lu-SN201 in MC38 tumor-bearing mouse. The graph presents % ID/g in the ROIs, where bars show the mean ± SD error from n = 3 representative animals per timepoint. Arrows; orange, tumor; green, liver; and blue, spleen.
Full article on pubs.acs.org
Bitte kontaktieren Sie uns für technische Informationen und Unterstützung jeglicher Art in Zusammenhang mit unseren Entwicklungen und Produkten.
Kontaktformular